Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

35.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
MicroRNAs01:22

MicroRNAs

3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Experimental RNAi02:15

Experimental RNAi

6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
Regulation of Expression at Multiple Steps01:23

Regulation of Expression at Multiple Steps

873
The gene expression in cells is regulated at different stages: (i) transcription, (ii) RNA processing, (iii) RNA localization, and (iv) translation. Transcriptional regulation is mediated by regulatory proteins such as transcription factors, activators, or repressors—these control gene expression by initiating or inhibiting the transcription of genes. Once a precursor or pre-mRNA is produced, it undergoes post-transcriptional modification, including 5' capping, splicing, and the...
873

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

scDeepAPA: a deep learning framework for single-cell alternative polyadenylation identification.

Briefings in bioinformatics·2026
Same author

Direct imaging-based gradient metasurface sensor enabling spectrometer-free ultrasensitive biomolecule detection.

Nature communications·2026
Same author

Dynamic needle tip positioning may improve first-attempt success rate in short-axis radial artery cannulation: A systematic review and meta-analysis of randomized trials.

The Journal of international medical research·2026
Same author

VIRSE: a variational Bayesian framework for RNA structural ensemble inference.

Briefings in bioinformatics·2026
Same author

Point-of-care ultrasound during trauma and critical care transport: a practical, safety-gated review.

Frontiers in public health·2026
Same author

Oxidative aging facilitates biological barrier penetration of polyethylene microplastics, amplifying systemic lipotoxicity in aquatic species.

Particle and fibre toxicology·2026

Related Experiment Video

Updated: Jun 7, 2025

Inducible and Reversible Dominant-negative DN Protein Inhibition
08:35

Inducible and Reversible Dominant-negative DN Protein Inhibition

Published on: January 7, 2019

8.3K

KRas plays a negative role in regulating IDO1 expression.

Xiandong Peng1, Eunji Lee1, Jialu Liang1

  • 1Division of Environmental Medicine, Department of Medicine, Grossman School of Medicine, New York University, 341 East 25th Street, New York, NY 10010, USA.

Translational Oncology
|November 17, 2024
PubMed
Summary
This summary is machine-generated.

Ras signaling negatively regulates Indoleamine 2,3-dioxygenase-1 (IDO1) expression while promoting Programmed cell death protein 1 ligand 1 (PD-L1) expression in KRas-mutant cancers. Inhibiting KRasG12C increases IDO1, suggesting combined KRas and IDO1 targeting for cancer therapy.

Keywords:
IDO1Immune checkpointInterferon-rKRasPD-L1

More Related Videos

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

6.7K
Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

8.4K

Related Experiment Videos

Last Updated: Jun 7, 2025

Inducible and Reversible Dominant-negative DN Protein Inhibition
08:35

Inducible and Reversible Dominant-negative DN Protein Inhibition

Published on: January 7, 2019

8.3K
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

6.7K
Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

8.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Ras proteins are crucial signaling mediators involved in cellular processes, with mutations linked to cancer and inflammatory diseases.
  • Immune checkpoint proteins (PD-1/PD-L1) and IDO1 are key players in tumor immune evasion.
  • The role of KRas in regulating IDO1 expression is not well understood, unlike its established effect on PD-L1.

Purpose of the Study:

  • To investigate the differential regulation of IDO1 and PD-L1 in KRas-mutant cancers.
  • To elucidate the impact of KRas signaling on IDO1 expression.
  • To explore the therapeutic potential of targeting KRas and IDO1 concurrently.

Main Methods:

  • Analysis of IDO1 and PD-L1 expression in KRas-mutant cancer cell lines and patient samples.
  • Treatment of KRasG12C-mutant cells with the specific inhibitor ARS-1620.
  • Investigation of Interferon-gamma (IFN-γ) induced IDO1 expression in the presence of active KRas.
  • Assessment of the involvement of the MAPK pathway in KRas inhibition-induced IDO1 expression.

Main Results:

  • IDO1 and PD-L1 are differentially regulated in KRas-mutant cancers.
  • KRasG12C inhibition by ARS-1620 increased IDO1 expression, inversely correlating with PD-L1 levels in H358 cells.
  • IDO1 expression was reduced in lung and pancreatic ductal adenocarcinoma patients with KRas mutations.
  • Constitutively active KRas attenuated IFN-γ-induced IDO1 expression.
  • KRas inhibition-induced IDO1 expression occurred independently of the MAPK pathway.

Conclusions:

  • KRas signaling negatively regulates IDO1 expression and positively regulates PD-L1 expression.
  • KRas inhibition can restore IDO1 expression, suggesting a potential therapeutic strategy.
  • Concurrent targeting of KRas and IDO1 may enhance treatment efficacy and overcome resistance to immune checkpoint blockade in KRas-mutant cancers.